This story originally ran on June 9.

By Adam Bonislawski

In a study published in the June issue of Nature Biotechnology, researchers from diagnostics firm Quanterix demonstrated the ability of the company's Single Molecule Array – or SiMoA – technology to detect prostate specific antigen in the blood of radical prostatectomy patients at concentrations as low as 0.4 fM – a sensitivity 1,700 times greater than that offered by conventional ELISA-based tests, according to the firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.